Key result
A 5% increase in mitral regurgitation fraction by CMR increased the risk of death, transplant, or LVAD in ischemic (HR 1.04; P=0.034) and non-ischemic (HR 1.09; P=0.011) cardiomyopathy.
Why the study?
Functional mitral regurgitation severity classification remains controversial, and it is unclear whether CMR quantitative assessment of FMR and LGE provides incremental risk stratification in ischemic and non-ischemic cardiomyopathy.
Does quantitative assessment of functional mitral regurgitation and myocardial scar by cardiac magnetic resonance predict the composite of all-cause death, heart transplant, or left ventricular assist device implantation in patients with cardiomyopathy (ejection fraction <50%)?
Cohort (n=1,414)
Does quantitative assessment of functional mitral regurgitation and myocardial scar by cardiac magnetic resonance predict the composite of all-cause death, heart transplant, or left ventricular assist device implantation in patients with cardiomyopathy (ejection fraction <50%)?
Effect estimate: HR 1.04 (ICM), HR 1.09 (NICM) (95% CI 1.01-1.07 (ICM), 1.02-1.16 (NICM))
p-value: p=0.034 (ICM), 0.011 (NICM)
Quantitative CMR assessment of mitral regurgitation fraction and late gadolinium enhancement provides important prognostic thresholds for risk stratification in patients with ischemic and non-ischemic cardiomyopathy.
MR fraction by CMR was associated with higher risk of death, transplant, or LVAD in cardiomyopathy; hypothesis-generating for quantitative thresholds in risk stratification.
BACKGROUND: The severity classification of functional mitral regurgitation (FMR) remains controversial despite adverse prognosis and rapidly evolving interventions. Furthermore, it is unclear if quantitative assessment with cardiac magnetic resonance can provide incremental risk stratification for patients with ischemic cardiomyopathy (ICM) or non-ICM (NICM) in terms of FMR and late gadolinium enhancement (LGE). We evaluated the impact of quantitative cardiac magnetic resonance parameters on event-free survival separately for ICM and NICM, to assess prognostic FMR thresholds and interactions with LGE quantification. METHODS: Patients (n=1414) undergoing cardiac magnetic resonance for cardiomyopathy (ejection fraction<50%) assessment from April 1, 2001 to December 31, 2017 were evaluated. The primary end point was all-cause death, heart transplant, or left ventricular assist device implantation during follow-up. Multivariable Cox analyses were conducted to determine the impact of FMR, LGE, and their interactions with event-free survival. RESULTS: There were 510 primary end points, 395/782 (50.5%) in ICM and 114/632 (18.0%) in NICM. Mitral regurgitation-fraction per 5% increase was independently associated with the primary end point, hazards ratios (95% CIs) of 1.04 (1.01–1.07; P =0.034) in ICM and 1.09 (1.02–1.16; P =0.011) in NICM. Optimal mitral regurgitation-fraction threshold for moderate and severe FMR were ≥20% and ≥35%, respectively, in both ICM and NICM, based on the prediction of the primary outcome. Similarly, optimal LGE thresholds were ≥5% in ICM and ≥2% in NICM. Mitral regurgitation-fraction×LGE emerged as a significant interaction for the primary end point in ICM ( P =0.006), but not in NICM ( P =0.971). CONCLUSIONS: Mitral regurgitation-fraction and LGE are key quantitative cardiac magnetic resonance biomarkers with differential associations with adverse outcomes in ICM and NICM. Optimal prognostic thresholds may provide important clinical risk prognostication and may further facilitate the ability to derive selection criteria to guide therapeutic decision-making.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) conducted a cohort in Cardiomyopathy (ischemic and non-ischemic) (n=1,414). Cardiac magnetic resonance assessment of mitral regurgitation fraction and late gadolinium enhancement was evaluated on All-cause death, heart transplant, or left ventricular assist device implantation (HR 1.04 (ICM), HR 1.09 (NICM), 95% CI 1.01-1.07 (ICM), 1.02-1.16 (NICM), p=0.034 (ICM), 0.011 (NICM)). A 5% increase in mitral regurgitation fraction by CMR increased the risk of death, transplant, or LVAD in ischemic (HR 1.04; P=0.034) and non-ischemic (HR 1.09; P=0.011) cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: